Cesium-131

Modern brachytherapy starts here.

Your Isotope Choice Makes a Difference

Not all brachytherapy radioisotopes are the same. Compared to alternative brachytherapy seeds, Cesium-131 offers the highest energy and shortest half-life.

Perspective Therapeutics is the only company in the world manufacturing and distributing Cesium-131 brachytherapy radioisotope seeds. These seeds were designed to treat a variety of cancers including prostate cancer, head & neck, lung and brain.

Cesium-131 can treat Prostate, Head and Neck, Lung, Brain and Gynecological cancers

Paladium-103

Introduced 2004

17 Day Half Life (18)

20.8 Kev

58 Days for 90% Dose

Detectable in the body for 170 Days

Cesium-131

Introduced 2004

9.7 Day Half-Life

The amount of time for the radiation to half. A shorter half life means quicker to PSA baseline. (8, 12, 13)

30.4 Kev

The energy level of the isotope. Higher energy leads to greater coverage of the infected organ.

33 Days for 90% Dose

Faster dose delivery rate.

Detectable in the body
for 97 Days

Iodine-125

Introduced 1965

60 Day Half Life (18)

28.5 Kev

204 Days for 90% Dose

Detectable in the body for 600 Days

Higher Energy

Higher Energy

Isoray’s proprietary isotope, Cesium Blu, has a higher energy allowing for a more uniform dose distribution with less overdosing than other permanent isotopes. (1)

Shorter Half-Life

Shorter Half-Life

Isoray’s proprietary isotope, Cesium Blu, has a shorter half-life than other commonly used isotopes for the treatment of cancer throughout the body, resulting in a shorter duration of radiation which contributes to a rapid resolution of patient side effects. (2)

Improved Coverage
of the Prostate

Isoray’s Cesium Blu proprietary permanent prostate cancer brachytherapy seeds allow for better dose homogeneity and the sparing of the urethra and rectum while providing comparable prostate coverage compared to other seeds with comparable or fewer seeds and needles. (3, 4, 5, 6)

Armpilla C, Dale R, Coles I, et al. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Rad Onc Biol Phys 2003; 55:378-385.

Insert Image Here

Higher Energy

Higher Energy

Isoray’s proprietary isotope, Cesium-131, has a higher energy allowing for a more uniform dose distribution with less overdosing than other permanent isotopes. (1)
Insert Image Here

Shorter Half-Life

Shorter Half-Life

Isoray’s proprietary isotope, Cesium-131, has a shorter half-life than other commonly used isotopes for the treatment of cancer throughout the body, resulting in a shorter duration of radiation which contributes to a rapid resolution of patient side effects. (2)
Insert Image Here

Improved Coverage of the Prostate

Improved Coverage of the Prostate

Cesium-131 proprietary permanent prostate cancer brachytherapy seeds allow for better dose homogeneity and the sparing of the urethra and rectum while providing comparable prostate coverage compared to other seeds with comparable or fewer seeds and needles. (3, 4, 5, 6)
Insert Image Here

Rapid Resolution of Side effects

Rapid Resolution of Side effects

Our proprietary isotope, Cesium-131, has a shorter half-life than other commonly used isotopes for the treatment of cancer throughout the body, resulting in a shorter duration of radiation which contributes to a rapid resolution of patient side effects. (7, 8, 9, 10)
Insert Image Here

Higher Biologically Effective Dose

Higher Biologically Effective Dose

Cesium-131 also delivers a higher ‚Äúbiological effective dose‚ÄĚ or BED compared to I-125 or Pd-103 across a wide range of tumor types. (11)
Insert Image Here

PSA Control

PSA Control

Investigators tracking PSA in both single arm and randomized prostate cancer treatment trials have concluded that Cesium-131 PSA response rates have similar early tumor control to I-125, which was previously considered the gold standard in permanent seed brachytherapy. (8, 12, 13)
Treats cancer at the source

Treats cancer
at the source

Quick recovery time for most patients

Quick recovery time for most patients

0
Plus
Patients have experienced the power of Cesium-131 for treating cancer.

A Modern Toolset for All Techniques of LDR Brachytherapy

We understand that every clinician has different requirements and methods of working, that’s why we offer a range of solutions that are designed to make your life easier and more cost-efficient.

From loose seeds and preloaded needles to cartridges and braided sutures we have not only what you need but what your patients require

Product links / images in here

Want to know more about the versatility of Cesium-131

Resources

1. Prestidge B.R., Bice W.S., Jurkovic I., et al. Cesium-131 Permanent Prostate Brachytherapy: An Initial Report. Int. J. Radiation Oncology Biol. Phys. 2005: 63 (1) 5336-5337.

2. Neill B, et al. The Nature and Extent of Urinary Morbidity in Relation to Prostate Brachytherapy Urethral Dosimetry. Brachytherapy 2007:6(3)173-9.

3. Musmacher JS, et al. Dosimetric Comparison of Cesium-131 and Palladium-103 for Permanent Prostate Brachytherapy. Int. J. Radiation Oncology Biol. Phys. 2007:69(3)S730-1.

4. Yaparpalvi¬†R, et al.¬†Is Cs-131 or I-125 or Pd-103 the ‚ÄúIdeal‚ÄĚ Isotope for Prostate Boost Brachytherapy? A¬†Dosimetric¬†View Point.¬†Int. J. Radiation Oncology Biol. Phys. 2007:69(3)S677-8.

5. Sutlief S, et al. Cs-131 Prostate Brachytherapy and Treatment Plan Parameters. Medical Physics 2007:34(6)2431.

6. Yang R, et al. Dosimetric Comparison of Permanent Prostate Brachytherapy Plans Utilizing Cs-131, I-125 and Pd-103 Seeds. Medical Physics 2008:35(6)2734.

7. Prestidge B, et. al. Clinical Outcomes of a Phase-II, Multi-institutional Cesium-131 Permanent Prostate Brachytherapy Trial. Brachytherapy. 2007: 6 (2)78.

8. Moran B, et al. Cesium-131 Prostate Brachytherapy: An Early Experience. Brachytherapy 2007:6(2)80.

9. Jones A, et al. IPSS Trends for Cs-131 Permanent Prostate Brachytherapy. Brachytherapy 2008:7(2)194.

10. DeFoe SG, et al. Is There Decreased Duration of Acute Urinary and Bowel Symptoms after Prostate Brachytherapy with Cesium 131 Radioisotope? Int. J. Radiation Oncology Biol. Phys. 2008:72(S1)S317.

 

11. Armpilia CI, Dale RG, Coles IP et al. The Determination of Radiobiologically Optimized Half-lives for Radionuclides Used in Permanent Brachytherapy Implants. Int. J. Radiation Oncology Biol. Phys. 2003; 55 (2): 378-385.

12. Bice W, et. al. Recommendations for permanent prostate brachytherapy with 131Cs: a consensus report from the Cesium Advisory Group. Brachytherapy 2008:7(4)290-296.

13. Platta CS, et al. Early Outcomes of Prostate Seed Implants with 131Cs: Toxicity and Initial PSA Dynamics from a Single Institution. Int. J. Radiation Oncology Biol. Phys. 2008:72(S1)S323-4.

14. Tomaszewski JJ, et al. Cesium 131 versus iodine 125 implants for prostate cancer: evaluation of early PSA response. The Canadian Journal of Urology. 2010;17(5): 5360-5364.

15. R.M. Benoit, R.P. Smith, S. Beriwal. Five Year Prostate-specific Antigen Outcomes after Caesium Prostate Brachytherapy. Clinical Oncology. 26 (2014) 776 780.

16. Brian J. Moran, MD, Michelle H. Braccioforte, MPH. Prostate Cancer Foundation of Chicago, Westmont, IL. PSA Outcomes in a Single Institution, Prospective Randomized 131Cs/125I Permanent Prostate Brachytherapy Trial Abstracts / Brachytherapy. 13 (2014) S15eS126.

17. Amit B. Shah, MD, Arnav A. Shah, Gregory A. Fortier, MD. Radiation Oncology, York Cancer Center, Wellspan Health, York, PA. A Comparison of AUA Symptom Scores following Permanent Low-Dose-Rate Prostate Brachytherapy with Iodine-125 and Cesium-131, Abstracts / Brachytherapy 12 (2013) S11eS77.

18. Herstein A, Wallner K, Merrick G, Mitsuyama H, Armstrong J, True L, Cavanagh W, Butler W. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial. Cancer J. 2005 Sep-Oct;11(5):385-9.

Scroll to top